Zhidong Pei

机构：Luoyang Central Hospital Affiliated to Zhengzhou University

发表论文 15 篇 · 总被引 108 次 · h-index 6

代表论文

• Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer (2019 · Translational Lung Cancer Research · 被引 36)
• Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial (2022 · Cancer Immunology Immunotherapy · 被引 22)
• MiR‐1224‐5p acts as a tumor suppressor via inhibiting the malignancy of rectal cancer through targeting SLC29A3 (2020 · IUBMB Life · 被引 18)
• Integration of High-Resolution LC-Q-TOF Mass Spectrometry and Multidimensional Chemical−Biological Analysis to Detect Nanomolar-Level Acetylcholinesterase Inhibitors from Different Parts of Zanthoxylum nitidum (2024 · Journal of Agricultural and Food Chemistry · 被引 9)
• Oncogenic microRNA-301b regulates tumor repressor dystrobrevin alpha to facilitate cell growth, invasion and migration in esophageal cancer (2020 · Esophagus · 被引 8)
• A strategy to distinguish similar traditional Chinese medicines by liquid chromatography–mass spectrometry, electronic senses, and gas chromatography–ion mobility spectrometry: Marsdeniae tenacissimae Caulis and Paederiae scandens Caulis as examples (2024 · Phytochemical Analysis · 被引 6)